Exhibit 99.1

 

 

Marker Therapeutics Reports First Quarter 2020 Operating and Financial Results

 

Company to host conference call and webcast today at 5:00pm EDT

 

Houston, TX—May 11, 2020—Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the first quarter ended March 31, 2020.

 

“While we are eager to initiate our planned Phase 2 trial with our novel MultiTAA-specific T cell therapy in patients with acute myeloid leukemia (AML), we anticipate that the initiation of our trial will be delayed by the impacts the COVID-19 pandemic has had on our clinical trial partners and throughout our supply chain. As a result of the uncertainty, we believe it is prudent to withdraw our prior guidance on the timing of this trial until the outlook clarifies,” said Peter L. Hoang, President & CEO of Marker Therapeutics. “Despite these pandemic-related effects, we remain optimistic that when the study opens, there will be significant patient interest. We are moving expediently in the interim to secure clinical trial sites and are monitoring the situation closely to prioritize the health and wellness of our employees and the patients we serve.”

 

Continued Mr. Hoang: “We continue to be encouraged by the potential of our MultiTAA-specific T cell therapy to change the treatment paradigm for patients with both liquid and solid tumors. Recently, we received Orphan Drug designation from the U.S. FDA for MT-401, our MultiTAA-specific T cell product candidate to treat patients with AML post-stem cell transplant, our lead indication. Additionally, we are looking forward to soon reporting an update from an ongoing academic-sponsored trial in pancreatic adenocarcinoma, which will be presented during the upcoming ASCO annual meeting.”

 

 

PROGRAM UPDATES

 

Multi-Antigen Targeted (MultiTAA) T Cell Therapies

 

Phase 2 AML Trial Update
Due to the COVID-19 pandemic, Marker expects to be delayed in initiating its planned Phase 2 trial in post-transplant AML patients per previously communicated timelines. Under an amended trial protocol announced in February 2020, the U.S. FDA cleared the Company to initiate the trial, beginning with a safety lead-in. Marker has paused opening the study for enrollment of the first three patients, as the manufacturing facility it utilizes to supply study drug remains closed during the pandemic. The Company continues to identify potential trial sites in the interim, in addition to establishing its own manufacturing facility. The latter portion of the safety lead-in, which involves use of a new reagent, remains on hold until the FDA reviews and accepts the final data and certificate of analysis. The alternate supplier providing these has informed the Company that it will be delayed in providing the reagent.

 

 

Orphan Drug Designation Granted for MultiTAA T Cell Therapy in AML

In April, the FDA’s Office of Orphan Products Development granted Orphan Drug designation to MT-401, Marker’s MultiTAA-specific T cell product candidate for the treatment of patients with post-transplant AML. Orphan designation is granted to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases or conditions affecting fewer than 200,000 people in the U.S.

 

Pancreatic Cancer Data Update During ASCO

Updated data from an ongoing Phase 1/2 clinical trial being conducted with Marker’s MultiTAA-specific T cell product at the Baylor College of Medicine (BCM) in patients with pancreatic adenocarcinoma will be presented during the Annual Meeting of the American Society of Clinical Oncology (ASCO)—which due to the COVID-19 pandemic, will be held virtually. As previously reported, in the front-line treatment arm in combination with standard-of-care chemotherapy, clinical benefit was observed in correlation with the post-infusion detection of tumor-reactive T cells in patients’ peripheral blood. These T cells exhibited activity against both targeted antigens and non-targeted TAAs, indicating induction of antigen spreading. To date, there has not been any cytokine release syndrome or neurotoxicity observed in this trial.

 

 

T Cell-Based Vaccines

 

Phase 2 Triple Negative Breast Cancer Trial Results
Marker’s T cell-based vaccine program in triple negative breast cancer has delivered the following results as of September 30, 2019:

 

·

Based on a preliminary analysis of 34 patients enrolled in the triple negative breast cancer trial, 31 patients showed meaningful immune response to vaccine treatment;

 

·

Of 80 patients treated at 11 clinical sites, 16 have shown disease progression following treatment with TPIV200.

  

FINANCING UPDATE

 

·

On March 2, 2020, Marker announced that the Company entered into a Common Stock Purchase Agreement of up to $30 million with Aspire Capital Fund, LLC, a Chicago-based institutional investor and long-term Marker shareholder.

 

FIRST QUARTER 2020 FINANCIAL RESULTS

 

Cash Position and Guidance: At March 31, 2020, Marker had cash and cash equivalents of $40.3 million. The Company believes that its existing cash and cash equivalents will fund its operating expenses and capital expenditure requirements into the second quarter of 2021.

 

R&D Expenses: Research and development expenses were $3.8 million for the quarter ended March 31, 2020 compared to $2.8 million for the quarter ended March 31, 2019. The increase was primarily attributable to headcount-related personnel expenses.

  

 

G&A Expenses: General and administrative expenses were $2.8 million for the quarter ended March 31, 2020 and March 31, 2019.

 

Net Loss: Marker reported a net loss of $6.5 million for the quarter ended March 31, 2020, compared to a net loss of $5.3 million for the quarter ended March 31, 2019.  

 

Conference Call and Webcast

The Company will host a webcast and conference call to discuss its first quarter 2020 financial results and provide a corporate update today at 5:00 p.m. EDT.

 

The webcast will be accessible in the Investors section of the Company’s website at markertherapeutics.com. Individuals can participate in the conference call by dialing 877-407-8913 (domestic) or 201-689-8201 (international) and referring to the “Marker Therapeutics First Quarter 2020 Earnings Call.”

 

The archived webcast will be available for replay on the Marker website following the event.

 

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

 

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts

 

 

Forward-Looking Statement Disclaimer
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies and our TPIV200 program; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the potential benefits of orphan drug designation; the impact of the COVID-19 pandemic; and the timing and success of our clinical trials, as well as clinical trials conducted by our collaborators. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

 

   

Marker Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)

  

		March 31,				December 31,
		2020				2019
ASSETS
Current assets:
Cash and cash equivalents		$	40,255,062			$	43,903,949
Prepaid expenses and deposits			1,716,092				1,526,442
Interest receivable			24,605				56,189
Total current assets			41,995,759				45,486,580
Non-current assets:
Property, plant and equipment, net			482,084				417,528
Right-of-use assets, net			407,813				455,174
Total non-current assets			889,897				872,702
Total assets		$	42,885,656			$	46,359,282
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities		$	2,955,293			$	1,757,680
Lease liability			209,081				204,132
Warrant liability			-				31,000
Total current liabilities			3,164,374				1,992,812
Non-current liabilities:
Lease liability, net of current portion			226,111				280,247
Total non-current liabilities			226,111				280,247
Total liabilities			3,390,485				2,273,059
Commitments and contingencies			-				-
Stockholders' equity:
Preferred stock - $0.001 par value, 5 million shares authorized and 0 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively			-				-
Common stock, $0.001 par value, 150 million shares authorized, 46.5 million and 45.7 million shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively			46,532				45,728
Additional paid-in capital			373,467,697				371,573,909
Accumulated deficit			(334,019,058	)			(327,533,414	)
Total stockholders' equity			39,495,171				44,086,223
Total liabilities and stockholders' equity		$	42,885,656			$	46,359,282

   

 

Marker Therapeutics, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)

  

		For the Three Months Ended
		March 31,
		2020				2019
Operating expenses:
Research and development		$	3,816,618			$	2,832,695
General and administrative			2,826,995				2,805,775
Total operating expenses			6,643,613				5,638,470
Loss from operations			(6,643,613	)			(5,638,470	)
Other income (expense):
Change in fair value of warrant liabilities			31,000				(9,000	)
Interest income			126,969				328,545
Net loss		$	(6,485,644	)		$	(5,318,925	)
Net loss per share, basic and diluted		$	(0.14	)		$	(0.12	)
Weighted average number of common shares outstanding			46,084,383				45,465,754

  

 

Marker Therapeutics, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)

  

		For the Three Months Ended
		March 31,
		2020				2019
Cash Flows from Operating Activities:
Net loss		$	(6,485,644	)		$	(5,318,925	)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization			35,265				10,514
Changes in fair value of warrant liabilities			(31,000	)			9,000
Stock-based compensation			1,344,592				1,525,976
Amortization on right-of-use assets			47,361				44,211
Changes in operating assets and liabilities:
Prepaid expenses and deposits			(189,650	)			(74,716	)
Interest receivable			31,584				(4,023	)
Accounts payable and accrued expenses			1,197,613				(27,628	)
Lease liability			(49,187	)			(44,575	)
Net cash used in operating activities			(4,099,066	)			(3,880,166	)
Cash Flows from Investing Activities:
Purchase of property and equipment			(99,821	)			(223,126	)
Net cash used in investing activities			(99,821	)			(223,126	)
Cash Flows from Financing Activities:
Proceeds from exercise of stock options			-				57,744
Proceeds from exercise of warrants			550,000				5,379
Net cash provided by financing activities			550,000				63,123
Net decrease in cash			(3,648,887	)			(4,040,169	)
Cash and cash equivalents at beginning of the period			43,903,949				61,746,748
Cash and cash equivalents at end of the period		$	40,255,062			$	57,706,579

  

 

Contacts

 

Investors

Solebury Trout

Chiara Russo

(617) 221-9197

crusso@soleburytrout.com

 

Media

Solebury Trout

Amy Bonanno

(914) 450-0349

abonanno@soleburytrout.com

 

 

###